Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.18 USD
Change Today -0.08 / -2.45%
Volume 8.6K
ONCS On Other Exchanges
As of 11:31 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/1/14 - $13.19
52 Week Low
11/18/15 - $2.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company has also completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in Merkel cell carcinoma. It is also conducting four additional clinical trials of ImmunoPulse with DNA-encoded IL-12 comprising OMS-I100 Addendum and CC-15852 in metastatic melanoma, OMS-I130 in head and neck cancer, and OMS-I140 in triple-negative breast cancer. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of combination therapy with KEYTRUDA (pembrolizumab), Merck & Co.’s anti-PD-1 therapy, and ImmunoPulse IL-12 in metastatic melanoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

53 Employees
Last Reported Date: 10/14/15
Founded in 2008

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $531.1K
Chief Financial Officer
Total Annual Compensation: $20.3K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $405.8K
Chief Medical Officer
Total Annual Compensation: $260.7K
Chief Legal and Compliance Officer
Total Annual Compensation: $208.3K
Compensation as of Fiscal Year 2015.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer

OncoSec Medical Incorporated announced that the company has enrolled the first patient into a pilot biomarker trial of ImmunoPulse™ IL-12 in patients with triple negative breast cancer (TNBC). ImmunoPulse™ IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to enhance tumor immunogenicity, leading to increased tumor infiltrating lymphocytes (TILs) and pro-inflammatory cytokines. Previous studies have demonstrated that breast cancer patients whose tumors are associated with markers of inflammation, such as the presence of TILs, have better clinical outcomes. These data have initiated an effort by an international consortium to develop guidelines and recommendations for the routine evaluation of TILs for breast cancer. Further, preliminary data reported at the 2014 San Antonio Breast Cancer Symposium indicate that TNBC is responsive to cancer immunotherapies, such as anti-PD-1/PD-L1 checkpoint therapies. However, response rates in these TNBC patients, who were selected for study participation based upon TIL status, were only 18% to 33%. Melinda L. Telli, MD, Assistant Professor of Medicine (Oncology) and Irene Wapnir, MD, Professor of Surgery (General Surgery), are leading this clinical trial at Stanford University Medical Center. Approximately 10 patients are planned for enrollment into this trial. The primary objective of the study is to evaluate the potential of ImmunoPulse™ IL-12 to promote a pro-inflammatory molecular and histological signature in tumor samples obtained from study participants. Secondary objectives include: evaluation of safety and tolerability; evaluation of local ablative effect (% necrosis); and description of other evidence of anti-tumor activity.

OncoSec Medical Incorporate Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2015

OncoSec Medical Incorporated reported consolidated earnings results for the fourth quarter and full year ended July 31, 2015. For the quarter, the company’s net loss was $6.5 million or $0.48 per share compared to $3.6 million or $0.30 per share a year ago. For the year, the company’s net loss was $21.2 million or $1.67 per share compared to $12.0 million or $1.26 per share a year ago. The increase in net loss for the year ended July 31, 2015, compared with the same period in 2014, resulted primarily from an increase in headcount as OncoSec continues to grow its discovery research and clinical teams, additional outside services costs to support its device development and clinical activities and corporate communication, financing and other administrative investments to expand investor awareness and list the company on The Nasdaq Stock Market. There were no revenues for the fiscal years ended July 31, 2015 or July 31, 2014. Loss from operations was $21,241,142 compared to $11,949,660 a year ago. Net loss before income taxes was $21,241,142 compared to $11,970,344 a year ago. Net cash used in operating activities was $17,651,470 compared to $8,980,473 a year ago. Purchases of property and equipment were $1,412,217 compared to $512,500 a year ago.

OncoSec Medical Incorporated, Q4 2015 Earnings Call, Oct 15, 2015

OncoSec Medical Incorporated, Q4 2015 Earnings Call, Oct 15, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $3.18 USD -0.08

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ONCOSEC MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at